Evidence map›Paper›PMID 24855404›Full record

ReviewClinical Medicine Insights. Oncology2014

What is the Best Treatment for a Cancer Patient with Thrombosis?

Miguel Barbosa

Abstract readReview
In one paragraph

Review in Clinical Medicine Insights. Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Anti-lymphangiogenesis for boosting drug accumulation in tumors.Signal transduction and targeted therapy · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Cancer-associated thrombosis: an overview.Clinical Medicine Insights. Oncology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Miguel BarbosaMedical Oncology Department, Centro Hospitalar Trás-os-Montes e Alto Douro, Av Noruega, Lordelo, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between venous thromboembolism and cancer has been known for many years, and there is solid scientific evidence addressing the adequate treatment of this condition in oncology patients. However, established prescribing habits, individual patient challenges, and uncertainty concerning treatment justifies poor adherence to published guidelines. This paper reviews venous thromboembolism treatment while focusing on vitamin K antagonists, low-molecular-weight heparins, and novel oral anticoagulants, namely in terms of their efficacy and limitations.

Indexed as

cancerlow-molecular-weight heparinoral anticoagulantsthrombosisvenous thromboembolismvitamin K antagonists

Identifiers

PMID24855404
PMCPMC4011719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.